AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16095461 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwashed filtered shed blood (USB) return (Group F40)
Number of subjects: 48
Study 16095461 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-reduction filter (LRF) return (Group LRF)
Number of subjects: 48
Study 16095461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no USB or ABT)
Number of subjects: 48
Study 12403958 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg trafermin
Number of subjects: 286
Study 12403958 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg trafermin
Number of subjects: 286
Study 12403958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 12403958 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg trafermin (post hoc subgroup analysis)
Number of subjects: 286
Study 11064879 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making and risk-reduction program (workshop lasting one day with five one-hour units)
Number of subjects: 64
Study 7791258 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25 mg, administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle)
Number of subjects: 170
Study 7791258 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (300 mg, administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle)
Number of subjects: 170
Study 7791258 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle)
Number of subjects: 170
Study 2146357 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpatory pain over osseous structures
Number of subjects: 46
Study 2146357 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpatory pain in paraspinal soft-tissues
Number of subjects: 46
Study 2146357 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of temperature differences (≥ 1.5 degrees F)
Number of subjects: 46
Study 2146357 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection for segmental abnormality
Number of subjects: 46
Study 2146357 — intervention group
Group type: EXPERIMENTAL
Intervention: Active motion palpation
Number of subjects: 46
Study 2146357 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive motion palpation
Number of subjects: 46
Study 2146357 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle tension palpation
Number of subjects: 46
Study 2146357 — intervention group
Group type: EXPERIMENTAL
Intervention: Misalignment palpation
Number of subjects: 46
Study 2146357 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite joint abnormality index (summed positive findings for eight dimensions)
Number of subjects: 46
Study 2146357 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimension index using four most reliable dimensions
Number of subjects: 46
Study 2146357 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement in lower lumbar spine
Number of subjects: 46
Study 29779834 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (weekly sessions for 12 months with home-based assessments and advice, n=100)
Number of subjects: 243
Study 29779834 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity control (home-based assessments and advice only, n=99)
Number of subjects: 243
Study 29779834 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (receiving paediatrician assessment with dietitian input and physical activity/nutrition support, n=44)
Number of subjects: 243
Study 28782697 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachioradialis release (Group A)
Number of subjects: 74
Study 28782697 — intervention group
Group type: COMPARATOR
Intervention: No brachioradialis release (Group B)
Number of subjects: 74
Study 26303326 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 40 Hz stimulation therapy
Number of subjects: 0
Study 26303326 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 Hz stimulation
Number of subjects: 0
Study 26303326 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 Hz stimulation
Number of subjects: 0
Study 26303326 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst stimulation
Number of subjects: 0
Study 26303326 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study 23374024 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked only
Number of subjects: 40
Study 23374024 — intervention group
Group type: EXPERIMENTAL
Intervention: Random only
Number of subjects: 40
Study 23374024 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked-then-Random
Number of subjects: 40
Study 23374024 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-then-Blocked
Number of subjects: 40
Study 23374024 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed practice schedules (Blocked-then-Random and Random-then-Blocked)
Number of subjects: 40
Study 21600592 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose methylprednisolone (30 mg/kg per dose, 8 hours preoperatively and operatively)
Number of subjects: 76
Study 21600592 — intervention group
Group type: COMPARATOR
Intervention: Single-dose methylprednisolone (30 mg/kg per dose, operatively)
Number of subjects: 76
Study 19249999 — intervention group
Group type: EXPERIMENTAL
Intervention: RES (Resistance Training)
Number of subjects: 21
Study 19249999 — intervention group
Group type: EXPERIMENTAL
Intervention: RES-C (Resistance Training + Chiropractic Treatment)
Number of subjects: 21
Study 16977477 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (3.5 mg/day during weeks 1 and 4; 7 mg/day during weeks 2 and 3)
Number of subjects: 11
Study 16977477 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 11
Study 16977477 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 11
Study 15267123 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/daily (1000 patients)
Number of subjects: 2000
Study 15267123 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 100 mg/weekly i.m. (800 patients)
Number of subjects: 2000
Study 15267123 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/daily (100 patients)
Number of subjects: 2000
Study 15267123 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/daily (100 patients)
Number of subjects: 2000
Study 11158861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.4 mg/d)
Number of subjects: 1054
Study 11158861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1054
Study 9258982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 10 mg controlled-release tablet ingested 2 hr after breakfast
Number of subjects: 31
Study 9258982 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin 10 mg controlled-release tablet ingested during fasting
Number of subjects: 31
Study 9258982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 10 mg controlled-release tablet ingested 1 hr before breakfast
Number of subjects: 31
Study 8289615 — intervention group
Group type: COMPARATOR
Intervention: Cyclists (C)
Number of subjects: 16
Study 3103540 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK combined with Tegafur (FT)
Number of subjects: 3630
Study 3103540 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC, FT and PSK
Number of subjects: 3630
Study 3103540 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC, FT, PSK and OK-432
Number of subjects: 3630
Study 3103540 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy with MMC, FT, PSK and OK-432
Number of subjects: 3630
Study 31644372 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 0
Study 29095201 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Bike
Number of subjects: 32
Study 29095201 — intervention group
Group type: COMPARATOR
Intervention: Bike
Number of subjects: 32
Study 27492018 — intervention group
Group type: EXPERIMENTAL
Intervention: K2 tablet (12.4% w/w Kollidon(®) SR)
Number of subjects: 0
Study 27492018 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release tablet (R)
Number of subjects: 0
Study 25522560 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolides
Number of subjects: 165
Study 25522560 — intervention group
Group type: COMPARATOR
Intervention: Cephalosporins
Number of subjects: 165
Study 22515904 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasonic irrigation (CUI)
Number of subjects: 360
Study 22515904 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation (PUI)
Number of subjects: 360
Study 22515904 — intervention group
Group type: COMPARATOR
Intervention: Positive pressure irrigation (PPI)
Number of subjects: 360
Study 20450670 — intervention group
Group type: EXPERIMENTAL
Intervention: OCCI (on-axis clear corneal incision)
Number of subjects: 39
Study 20450670 — intervention group
Group type: COMPARATOR
Intervention: TCCI (temporal clear corneal incision)
Number of subjects: 39
Study 19046225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 86
Study 19046225 — intervention group
Group type: COMPARATOR
Intervention: Blood glucose awareness training (BGAT)
Number of subjects: 86
Study 16494857 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 40
Study 16494857 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 40
Study 15259901 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine
Number of subjects: 28
Study 15259901 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine
Number of subjects: 28
Study 15259901 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 28
Study 11777120 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving communication training (PSCT) alone, 18 sessions
Number of subjects: 97
Study 11777120 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior management training (BMT) for 9 sessions followed by PSCT for 9 sessions (BMT/PSCT)
Number of subjects: 97
Study 11777120 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (PSCT and BMT/PSCT)
Number of subjects: 97
Study 9298779 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% maximal exercise intensity swimming intervals (95% ITS)
Number of subjects: 8
Study 9298779 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% maximal exercise intensity swimming intervals (70% ITS)
Number of subjects: 8
Study 9298779 — intervention group
Group type: COMPARATOR
Intervention: Control samples taken on a rest day (R)
Number of subjects: 8
Study 8410398 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment associated with higher mortality
Number of subjects: 230
Study 8410398 — intervention group
Group type: COMPARATOR
Intervention: Treatment associated with lower mortality
Number of subjects: 230
Study 8410398 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients (with urinary incontinence or impotence)
Number of subjects: 230
Study 8410398 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic patients (without urinary incontinence or impotence)
Number of subjects: 230
Study 3104218 — intervention group
Group type: EXPERIMENTAL
Intervention: HB420 (3.5 mg/tablet)
Number of subjects: 22
Study 3104218 — intervention group
Group type: COMPARATOR
Intervention: HB419 (5 mg/tablet)
Number of subjects: 22
Study 30708349 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized multi-model cognitive training, 3-4 times per week for 6 months
Number of subjects: 141
Study 30708349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 141
Study 30708349 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized multi-model cognitive training
Number of subjects: 141
Study 28317094 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg.kg‐1
Number of subjects: 4494
Study 28317094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4494
Study 25566694 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion threshold <7 g/dl
Number of subjects: 200
Study 25566694 — intervention group
Group type: COMPARATOR
Intervention: Transfusion threshold 10 g/dl
Number of subjects: 200
Study 23307156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional motor skill training using a 3x1 array keypad for 30 minutes over two consecutive days.
Number of subjects: 0
Study 23307156 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidirectional motor skill training using a 3x3 array keypad for 30 minutes over two consecutive days.
Number of subjects: 0
Study 23307156 — intervention group
Group type: COMPARATOR
Intervention: Control group (FDI TMS-MEP stimulus-response curves).
Number of subjects: 0
Study 20859932 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation (8 sessions)
Number of subjects: 39
Study 20859932 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 39
Study 19880616 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study 19880616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17122226 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 140
Study 17122226 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral entropy monitoring
Number of subjects: 140
Study 17122226 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 140
Study 15177955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (0.5 mg/ml for 5 minutes)
Number of subjects: 60
Study 15177955 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 60
Study 11224634 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparin 5,000 units every 8 hours
Number of subjects: 936
Study 11224634 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily (plus two additional saline injections)
Number of subjects: 936
Study 9010944 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 30
Study 9010944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 30
Study 9010944 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 30
Study 9010944 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study 7899804 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteflene (Ro 42-1611) 300 mg or higher doses
Number of subjects: 54
Study 7899804 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteflene (Ro 42-1611) 100, 300, 900, 1800, 2700, and 3600 mg
Number of subjects: 54
Study 7899804 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteflene (Ro 42-1611)
Number of subjects: 54
Study 7899804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 3661277 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol expected
Number of subjects: 39
Study 3661277 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol expected
Number of subjects: 39
Study 3661277 — intervention group
Group type: EXPERIMENTAL
Intervention: None alcohol expected
Number of subjects: 39
Study 3661277 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumed
Number of subjects: 39
Study 3661277 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol consumed
Number of subjects: 39
Study 3661277 — intervention group
Group type: EXPERIMENTAL
Intervention: None alcohol consumed
Number of subjects: 39
Study 31209720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterilized probiotic with 5.85 g polydextrose daily for 1 week (Group A)
Number of subjects: 163
Study 31209720 — intervention group
Group type: COMPARATOR
Intervention: Sterilized probiotic without polydextrose daily for 1 week (Group B)
Number of subjects: 163
Study 29526580 — intervention group
Group type: EXPERIMENTAL
Intervention: Home particle repositioning maneuver (PRM) once weekly for five years
Number of subjects: 309
Study 29526580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home PRM)
Number of subjects: 309
Study 26607646 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp, 600 mAs, 35 ml CM at an injection rate of 3.5-4.5 ml/s
Number of subjects: 94
Study 26607646 — intervention group
Group type: COMPARATOR
Intervention: 100 kVp, 600 mAs, 70 ml CM at an injection rate of 4.5-5.5 ml/s
Number of subjects: 94
Study 25012543 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1402
Study 25012543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1402
Study 22815697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive exercises (CE)
Number of subjects: 36
Study 22815697 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive training (CP)
Number of subjects: 36
Study 20361904 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release (ER) at a daily dosage initiated at 20 mg/kg for 21 days
Number of subjects: 225
Study 20361904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 19368096 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily for 6 months
Number of subjects: 71
Study 19368096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 15910120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive switching tasks (verbal and nonverbal)
Number of subjects: 719
Study 16388203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 100
Study 16388203 — intervention group
Group type: COMPARATOR
Intervention: Isoxsuprine
Number of subjects: 100
Study 10577853 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (mitomycin 20 mg/m² IV on day 1, followed by tegafur 400 mg bid daily for 3 months)
Number of subjects: 148
Study 10577853 — intervention group
Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 148
Study 8914885 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million U streptokinase
Number of subjects: 52
Study 8914885 — intervention group
Group type: COMPARATOR
Intervention: 1.5 million U streptokinase
Number of subjects: 52
Study 1874226 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 in 1 femoral nerve block
Number of subjects: 0
Study 1874226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral cutaneous nerve block
Number of subjects: 0
Study 1874226 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 0
Study 7089645 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical clipping
Number of subjects: 200
Study 7089645 — intervention group
Group type: COMPARATOR
Intervention: Razor shaving
Number of subjects: 200
Study 30321061 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumenis® M22TM intense pulsed light (IPL)
Number of subjects: 40
Study 30321061 — intervention group
Group type: COMPARATOR
Intervention: 5% tea tree oil (control)
Number of subjects: 40
Study 29961161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 25 mg every 4 weeks (q4w)
Number of subjects: 0
Study 29961161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg every 4 weeks (q4w)
Number of subjects: 0
Study 29961161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 4 weeks (q4w)
Number of subjects: 0
Study 29961161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 2 weeks (q2w)
Number of subjects: 0
Study 29961161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26693901 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 5543
Study 26693901 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic Acid (ZA)
Number of subjects: 5543
Study 24652989 — intervention group
Group type: EXPERIMENTAL
Intervention: FC with rituximab (FCR)
Number of subjects: 0
Study 24652989 — intervention group
Group type: COMPARATOR
Intervention: FC
Number of subjects: 0
Study 24652989 — intervention group
Group type: EXPERIMENTAL
Intervention: FCR
Number of subjects: 0
Study 21956255 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 50 mg/day
Number of subjects: 0
Study 21956255 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg/day
Number of subjects: 0
Study 21956255 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 150 mg/day
Number of subjects: 0
Study 21956255 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (all doses)
Number of subjects: 0
Study 21410035 — intervention group
Group type: EXPERIMENTAL
Intervention: Neroli oil (experimental group)
Number of subjects: 27
Study 21410035 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (control group)
Number of subjects: 27
Study 17265519 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 (oxaliplatin/5‐fluorouracil/leucovorin)
Number of subjects: 0
Study 17265519 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/LV (leucovorin/5-fluorouracil)
Number of subjects: 0
Study 16241027 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dye
Number of subjects: 185
Study 16241027 — intervention group
Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 185
Study 16241027 — intervention group
Group type: COMPARATOR
Intervention: No antiseptic agent
Number of subjects: 185
Study 12914870 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg or carvedilol 25 mg twice daily after a 4-week dose titration period
Number of subjects: 49
Study 10340366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremacamra (367 microg per nostril per dose, total of 4.4 mg/d)
Number of subjects: 198
Study 10340366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 7546157 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA‐NOF (7.5 mg/kg)
Number of subjects: 12
Study 2006518 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental neoprene‐injected graft (group A)
Number of subjects: 17
Study 2006518 — intervention group
Group type: COMPARATOR
Intervention: Total pancreaticoduodenal graft with enteric diversion (group B)
Number of subjects: 17
Study 7011221 — intervention group
Group type: EXPERIMENTAL
Intervention: Early motion starting on postoperative day 1
Number of subjects: 36
Study 7011221 — intervention group
Group type: COMPARATOR
Intervention: Delayed motion starting on postoperative day 7
Number of subjects: 36